What are the symptoms and treatment of atypical pneumonia?

Symptoms of Atypical Pneumonia

The term "atypical pneumonia" should be abandoned because it incorrectly implies a characteristic clinical presentation—in reality, clinical features cannot reliably distinguish atypical from typical pneumonia, and symptoms overlap completely. 1

Why Clinical Differentiation Fails

Host factors such as age and comorbidities dominate the clinical presentation far more than the specific pathogen, making etiologic diagnosis impossible on clinical grounds alone. 2, 3

• No combination of history, physical examination, laboratory tests, or chest radiography can reliably differentiate typical from atypical pneumonia 3
• Pathogens traditionally labeled "atypical" can cause clinical syndromes ranging from subacute illness to fulminant life-threatening pneumonia, overlapping completely with "typical" bacterial presentations 3
• Mixed infections involving both bacterial and atypical pathogens occur in 3-40% of cases, further blurring any clinical distinctions 2, 3

Historical (But Unreliable) Clinical Features

While historically described, these features are not reliable for diagnosis:

• Slow, subacute progression over days to weeks (versus acute onset) 3, 4
• Low-grade fever rather than high fever 3, 4
• Prominent constitutional symptoms including malaise, headache, and myalgias 3, 4
• Minimal or absent focal chest findings on examination 3, 5
• Non-productive or minimally productive cough 4, 6

Age-Specific Presentations

• Elderly patients more frequently present with non-specific symptoms and are less likely to have fever than younger patients 1
• Mycoplasma pneumoniae accounts for 8-16% of hospitalizations in school-aged children and adolescents, characterized by slow progression and low-grade fever in pediatric populations 3
• Mycoplasma and Chlamydia psittaci infections are less frequent in the elderly 1

Extrapulmonary Manifestations

Atypical pathogens often cause extrapulmonary manifestations that distinguish them as systemic infectious diseases with a pulmonary component: 6

• Each atypical pathogen has a characteristic pattern of extrapulmonary organ involvement 6
• Mycoplasma pneumoniae and Chlamydia pneumoniae may exacerbate or cause asthma in adults 6
• Legionella can be differentiated from other pathogens by using a weighted point system based on characteristic extrapulmonary features 6

Common Causative Organisms

• Mycoplasma pneumoniae accounts for 13-37% of outpatient pneumonia episodes 2, 3
• Chlamydia pneumoniae is reported in up to 17% of outpatients with community-acquired pneumonia 2, 3
• Legionella species rates vary from 0.7% to 13% of outpatients 3
• Zoonotic pathogens include Chlamydia psittaci (psittacosis), Francisella tularensis (tularemia), and Coxiella burnetii (Q fever) 6

Critical Pitfall to Avoid

Do not delay or narrow antibiotic therapy based on presumed typical versus atypical distinction from clinical features. 3 All patients with community-acquired pneumonia should receive empiric antibiotic coverage for atypical pathogens because clinical features cannot reliably distinguish them 2.

---

Treatment of Atypical Pneumonia

Outpatient Treatment (Previously Healthy Patients)

For previously healthy patients with no recent antibiotic use, start a macrolide as first-line treatment (strong recommendation). 2, 3

• Azithromycin is first-line for Chlamydophila pneumoniae 2
• Doxycycline 100 mg twice daily for 7-14 days is an alternative option (weak recommendation) 2
• Macrolides are first-line treatment for Mycoplasma pneumoniae 2

Outpatient Treatment (Patients with Comorbidities)

For patients with comorbidities or risk factors, use combination therapy with a β-lactam plus a macrolide OR a respiratory fluoroquinolone alone. 2

• Elderly patients or those with comorbidities should be considered for respiratory fluoroquinolones or combination therapy due to potentially more severe disease 2

Inpatient Treatment (Non-ICU)

Use combination therapy with a β-lactam plus a macrolide for non-ICU hospitalized patients. 2

• β-lactam plus macrolide combination has stronger evidence than β-lactam plus fluoroquinolone 7

Inpatient Treatment (ICU/Severe CAP)

For severe CAP requiring ICU admission, use intravenous combination of a broad-spectrum β-lactam plus a macrolide OR a β-lactam plus a respiratory fluoroquinolone. 2

• Severe CAP is defined by septic shock requiring vasopressors or respiratory failure requiring mechanical ventilation 7

Treatment Duration and Timing

• Minimum of 5 days of therapy, with the patient being afebrile for 48-72 hours before discontinuation 2
• The first dose of antibiotic should be administered within 8 hours of hospital arrival to reduce 30-day mortality 2
• Patients should show clinical improvement within 48-72 hours of appropriate therapy 2

Pathogen-Specific Considerations

• Legionella pneumonia: Preferably treated with erythromycin 2-4 g for at least three weeks; alternatives include tetracyclines or quinolones 4
• Mycoplasma and Chlamydial infections: Erythromycin 2-4 g or doxycycline 200 mg daily 4
• Coxiella pneumonia: Tetracycline is preferred 4
• Psittacosis (ornithosis): Has high mortality and must be treated with tetracyclines immediately 4
• Quinolones and telithromycin have the highest level of anti-Legionella activity 6

Special Considerations for Severe Cases

• For hospitalized patients with severe pneumonia, Legionella urinary antigen testing should be considered 3, 7
• Add MRSA coverage if there is prior MRSA infection, recent hospitalization with IV antibiotics, or high local MRSA prevalence 7
• Add Pseudomonas coverage if there is prior Pseudomonas infection, structural lung disease, or recent hospitalization with IV antibiotics 7

Radiological Considerations

• Radiographic changes caused by atypical pathogens clear more quickly than those associated with typical bacterial pneumonia 1
• Radiological resolution often lags behind clinical improvement, particularly following Legionella and bacteraemic pneumococcal infection 1
• Radiological resolution is slower in the elderly and in cases with multilobe involvement 1